9vc uses tech to create, augment and invest in companies with late stage drug development programs
reincarnation

drugs to patients. value to investors. fast, with lower risk. morph untapped late clinical stage drugs and graft them onto promising companies or start new ones
tech + experience

proprietary search engine. tech bio partnerships to diligence and build. an experienced team of biotech and pharma builders, investors and senior execs with a track record of success
asset arbitrage

arbitrage works when we see value in something others do not. the 9vc infrastructure enables capturing this value with confidence, towards near term realization
TEAM
team with track record, relationships across VC, pharma, biotech, finance, tech
Anat Naschitz is CEO and Co-founder of 9xc, the connected gym for biopharma assets

anat naschitz
INVESTMENT TEAM
Investor, company and fund creator. Co-founded 89bio, acquired by Roche for $3.5bn. co-founder and partner, OrbiMed Israel. previously senior roles at McKinsey, Apax

pharma R&D leader
INVESTMENT TEAM
Former head of R&D of a big pharma, brought multiple blockbuster, curative drugs to market through acquisition and in house development.

tech/bio partners
TECH TEAM
premier computational R&D collaborators
Jan Schultink is Co-founder of 9xc, the connected gym for biopharma assets

jan schultink
TECH TEAM
Tech entrepreneur and builder across multiple substance domains, founded and built SlideMagic, previously senior roles at McKinsey
Jeremy Levin is a member of the Advisory Board of 9xc, the connected gym for biopharma assets

jeremy levin
ADVISORY BOARD
Chairman and CEO, OvidRx. Executive chairman, Opthea. Board member, Lundbeck. CEO, Teva. SVP BD, BMS. Global head of BD, Novartis. Chair, BIO
Aaron Gershenberg is a member of the Advisory Board of 9xc, the connected gym for biopharma assets

aaron gershenberg
ADVISORY BOARD
CEO of Blue Chip Funds of Funds, $10bn, premier access: Pinegrove, Silicon Valley Bank
Johan Luthman is a member of the Advisory Board of 9xc, the connected gym for biopharma assets

johan luthman
ADVISORY BOARD
R&D leader, senior exec. EVP & head of R&D, Lundbeck. 15 marketed drugs, ± 100 peer reviewed papers
Paul Sekhri is a member of the Advisory Board of 9xc, the connected gym for biopharma assets

paul sekhri
ADVISORY BOARD
CEO, vTv. 40+ boards eg Ipsen, Veeva. CEO Lycera, eGenesis, Cerimon. SVP IC Sanofi. Chief Strategy/BD, Teva. op.partner, TPG Biotech. CBO Ariad. SVP BD&L Novartis
Paul Biondi is a member of the Advisory Board of 9xc, the connected gym for biopharma assets

paul biondi
ADVISORY BOARD
General Partner, President, Flagship Pioneering Medicines. boards incl. Seres, Valo. SVP Strategy, BD, BMS. R&D leadership roles, BMS. principal, Mercer
PORTFOLIO
9vc.1: Athira (NASDAQ: ATHA)
PIPE

Athira, blessed with a strong team, committed blue-chip investors and phase 2 ready pipeline, is in-licensing a mid phase 3 asset to create a compelling late stage clinical development company.

Lasofoxifene, an oral small molecule combined with CDK4/6 inhibitor abemaciclib in an >50% enrolled, potentially registrational phase 3 trial, aims to provide a new, safe and efficacious standard of care to treat ESR1-mutant metastatic breast cancer in patients who have progressed on aromatase inhibitors and prior CDK4/6 inhibitors. Laxofoxifene is a potent Selective Estrogen Receptor Modulator (SERM) which, unlike SERDs, targets only breast cancer tissue rather than degrading estrogen in the entire body. A phase 2 trial combo, has shown strong efficacy and quality of life and health benefits.

In parallel, the company will continue to progress ATH-1105, a novel, orally available, next generation small molecule designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease. The company is planning to initiate a phase 2 clinical trial in ALS patients in early 2026.
- contact